Vaccination against IL-31 for the treatment of atopic dermatitis in dogs - 04/07/18
Doi : 10.1016/j.jaci.2017.12.994
Martin F. Bachmann, PhD a, b 
, Andris Zeltins, PhD c, d, Gints Kalnins, Dr med vet c, Ina Balke, PhD c, Nina Fischer, MSc Biol e, Ana Rostaher, Dr med vet e, Kaspars Tars, PhD c, Claude Favrot, Dr med vet e
, Andris Zeltins, PhD c, d, Gints Kalnins, Dr med vet c, Ina Balke, PhD c, Nina Fischer, MSc Biol e, Ana Rostaher, Dr med vet e, Kaspars Tars, PhD c, Claude Favrot, Dr med vet e a RIA Immunology, Inselspital, University of Bern, Bern, Switzerland
b Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
c Latvian Biomedical Research & Study Centre, Riga, Latvia
d Saiba GmbH, Alte Tösstalstr, Rämismühle, Switzerland
e Vetsuisse Faculty, Dermatology Unit, University of Zurich, Wonterthurerstrasse, Zurich, Switzerland
| This project was supported by funding of the Swiss National Science Foundation (SNF; grant no. CRSII3_154490) and Benchmark Ltd. |
|
| Disclosure of potential conflict of interest: M. F. Bachmann reports board membership as a shareholder of Saiba GmbH. A. Zeltins declares a grant and consultancy from Saiba GmbH; and employment from Latvian Biomedical Research and Study Centre, Riga, Latvia. G. Kalnins declares a grant from Saiba GmbH. I. Balke declares employment at Latvian Biomedical Research and Study Centre, Riga, Latvia; and grants/grants pending from the Latvian Council of Science. N. Fischer declares a grant from Benchmark; grants/pending grants from Waltham; and lecture fees from MSD. K. Tars declares a grant from Saiba GmbH. C. Favrot declares a grant from Benchmark; consultancy for Zenoaq, Elanco, Bayer, CEVA, and Genchis; and grants/pending grants from Tolerys and Royal Canin. A. Rostaher declares no relevant conflicts of interest. |
© 2018
American Academy of Allergy, Asthma & Immunology. Tous droits réservés.
Vol 142 - N° 1
P. 279 - juillet 2018 Retour au numéro
Article précédent
- Prenatal and early-life triclosan and paraben exposure and allergic outcomes
- Kathleen Lee-Sarwar, Russ Hauser, Antonia M. Calafat, Xiaoyun Ye, George T. O'Connor, Megan Sandel, Leonard B. Bacharier, Robert S. Zeiger, Nancy Laranjo, Diane R. Gold, Scott T. Weiss, Augusto A. Litonjua, Jessica H. Savage
- Activation of protease-activated receptor 2 leads to impairment of keratinocyte tight junction integrity
- Peter Nadeau, Mason Henehan, Anna De Benedetto
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?